Cost reduction of ECMO therapy is also critical. With the rising numbers of ECMO applications, cost effectiveness of the treatment plays
an important role for healthcare economics. Pandemias such as the swine flu outbreak in 2009 create sudden peaks of ECMO demand while current systems are too expensive to be kept in reserve.
Simplicity of operation is a must. Expanding indications and new user groups call for a reasonable practicability. ECMO is often used in an emergency situation. An easy operation secures treatment safety and outcome and has large impacts on time and effort of training and education.
Hemovent’s ECMO device is extremely robust, operates like a natural heart, weighs only about 2.2 lbs/1kg and needs neither battery nor software. For the first time ECMO can be deployed easily, fully mobile and cost-effective for a fast-growing patient population.
World’s Smallest and First Self-Contained Fully Portable ECMO System
Extra Corporeal Membrane Oxygenation (ECMO) saves lives. Every ECMO patient needs to be transported under severely restricted space conditions either within a hospital or from a referring clinic, or even from an emergency incident In the course of treatment patient mobilization is a critical success factor.
ECMO (Extracorporeal Membrane Oxygenation) is a procedure that uses a machine to take over the work of the lungs or eventually the heart and the lungs. ECMO is used for infants, children and adults. Extracorporeal means that the blood circulates outside of the body with the help of a machine.
Membrane Oxygenation, referred to as the “artificial lungs,” is a special part of the machine that puts oxygen into the blood and takes out carbon dioxide just like our lungs do.
What is the goal of ECMO?
The goal of ECMO is to insure that your loved one's body has enough oxygen by taking over the workload of reversible heart and/or lung disorders. ECMO will not heal your loved one's heart or the lungs, but it will allow time for them to rest and recover. Your loved one can be on ECMO for several days to a few weeks. When the heart or the lungs have healed and can work on their own, the support from ECMO is gradually removed. Individuals with severe but reversible heart or lung disorders that have not responded to the usual treatments of mechanical ventilation, medications and oxygen therapy are candidates for ECMO. For more information on ECMO, please click here.
Hemovent’s portable ECMO system is designed to reduce the footprint of required technology by 90%.
Every year millions of people have medical conditions that lead to cardiac and respiratory failure or a combination of both. Many of them have to be admitted to hospital emergency departments in often life-threatening situations.
ECMO (Extra Corporeal Membrane Oxygenation) therapy is used to treat acute respiratory and circulatory failure – a condition that affects about 12 million people worldwide every year. Recent advancements in the application of ECMO have led to significant improvements in clinical outcomes. Now clinicians urge for an even earlier ECMO application and a broadening of the indications. But there is a big drawback to standard ECMO reatment: it is not sufficiently portable.
Patient mobilization is key. Every ECMO patient needs to be transported under severely restricted space conditions either within the hospital, from a referring clinic or even from the field of an emergency incident. In the course of treatment patient mobilization is a critical success parameter for ECMO.